Gastrointestinal stromal tumors that metastasize cannot be controlled by systemic chemotherapy or radiotherapy; however, tumor control in such patients can be achieved with imatinib. The author of this Viewpoint discusses whether imatinib should be used as adjuvant therapy in patients who are at risk for developing metastasis, and whether tumor size is an appropriate criterion for such therapy.